In our final episode focused on the OX40 pathway and its emerging therapies, Dr. Joy Wan moderates a thoughtful discussion with two leaders from the patient advocacy community. Wendy Smith Begolka, MBS, Chief Program and Mission Officer at the National Eczema Association , and Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research , share their perspectives on incorporating patient priorities into clinical trials and effectively communicating with patients about new and emerging treatments. Disclosures: Joy Wan, MD - Sun Pharmaceuticals – consulting (DMC), Astria Therapeutics – consulting (ad board), Galderma – fellowship funding (paid to Johns Hopkins) Wendy Smith-Begolka, MBS - Amgen/Kyowa, Kirin, Pfizer, Sanofi – advisory board honoraria; Arcutis, Incyte, Galderma – speaker fees; Pfizer, Sanofi – research grants Korey Capozza, MPH - Advisory board honoraria from Amgen, Kyowa Kirin, Incyte, and Pfizer
